cagon, and insulin in the pancreas and corticotropin release by the adenohypophysis). AVP also regulates several behavioral and memory processes (6, 20) . These actions are mediated by activation of three specific seven-transmembrane G proteincoupled receptors named V 1a , V 1b , and V 2 R, which have been cloned in several species and characterized in a large number of tissues (2, 23, 44) . Of these three receptors, the V 1b R is the less documented and is still poorly understood. The human (8, 32) , rat (23, 41) , and mouse (48) isoforms have been cloned; the V 1b R is mainly involved in the stimulating effect of AVP on corticotropin secretion in the pituitary, and its role in stress and emotional situations is now established (1, 16) . As shown by RT-PCR, in situ hybridization, or immunohistochemistry, the V 1b R gene/protein is expressed not only in anterior pituitary but also in the brain (23, 47) and peripheral tissues such as the pancreas (49, 12) , adrenals (15) , small intestine, kidney (32) , various tumoral cells (small cell lung cancer and corticotropin-secreting tumors; see Ref. 9 and 26) and bronchial epithelial cells (3) , clearly suggesting that AVP may exert various actions by acting on extrapituitary V 1b R. However, because of the low expression level of the V 1b R in these tissues that already express considerable amounts of V 1a and/or V 2 R, major species differences in the pharmacology of existing reference AVP compounds, and the absence of totally selective and high-affinity V 1b ligands, a complete characterization of the V 1b R has been severely hampered. Very recently, the discovery of the first V 1b R agonist and antagonist gave the awaited tools needed to further investigate this receptor, namely d[cyclohexylalanine 4 ]AVP (d [Cha 4 ]AVP) and SSR-149415, respectively (10, 39) . The former results from structural modifications of the natural hormone AVP; synthetic peptides derived from [deaminocysteine 1 ,arginine 8 ]AVP (dAVP), modified in position 4 by various amino acid residues such as d [Cha 4 ] or lysine 4 to replace the glutamine 4 yielded high-affinity V 1b ligands. d [Cha 4 ]AVP constituted the first V 1b agonist available with excellent affinity for the human V 1b R; however, because of species differences, very common in the AVP domain, this peptide exhibits a mixed V 1b /V 2 pharmacological profile for the rat AVP isoforms (18) . The second molecule, SSR-149415, is an orally active nonpeptide antagonist possessing high and selective affinity for rat and human V 1b R in vitro and in vivo. This molecule also decreases anxiety in rodents and exerts marked antidepressant-like activity in several predictive animal models (39, 16) . This molecule has been now tritiated, and the present study provides a detailed biochemical characterization of [ 3 H]SSR-149415, the first nonpeptide antagonist radioligand available for labeling V 1b R. It was used for characterizing rodent (mouse, rat, and hamster) and human V 1b R, of native or recombinant origin, in binding and autoradiography studies. Moreover, using SSR-149415/ [ 3 H]SSR-149415, it was possible, for the first time, to extensively characterize the mouse V 1b R stably expressed in murine AtT20 pituitary cells in comparison with the human one in terms of binding properties, inositol phosphate (IP) production, Ca 2ϩ mobilization, and receptor internalization. DNA constructs. The cDNAs coding for the human (8) and the mouse (48) V 1bR were amplified by PCR, inserted in the HindIII-XbaI (human) or EcoRI-XbaI (mouse) sites of the expression vector pcDNA3, and named pcDNA-hV 1b and pcDNA-mV1b, respectively. The epidermal growth factor protein (EGFP)-tagged version of hV1 bR, phV3-EGFP, is described in Ref. 31 . The EGFP-tagged version of mV1 bR, pmV1b-EGFP, was obtained as follows: the 5Ј-EcoRI-EcoNI fragment from the plasmid pcDNA-mV 1b plus the 3Ј-EcoNI-KpnI fragment amplified by PCR from the same plasmid, including a KpnI site instead of the stop codon, were inserted simultaneously in frame in the EcoRI-KpnI sites of p-EGFP-N1. The constructs were verified by restriction enzyme digestion and DNA sequencing.
Biological materials. The hamster glucagonoma In-R1-G9 cells were kindly provided by Dr. Kimberly A. Matthews (Veterans Affairs Medical Center). Mouse corticotroph AtT20/D16V-F2 cells (CRL-1795) were from ATCC (Manassas, VA). AtT20 wild-type cells were transfected with 5 g/petri dish of the plasmids pcDNA-hV3, pcDNA-mV 1b, phV1b-EGFP, or pmV1b-EGFP using the Lipofectamine Plus Reagent according to the instructions of the manufacturer. Cells stably expressing wild-type receptors were selected with G418 (0.6 mg/ml). The clones were screened by [ 3 H]AVP binding and purified by the limited dilution technique. Cells stably expressing pmV 1b-EGFP and phV1b-EGFP were selected with G418 (0.6 mg/ml), the clones were purified by fluorescence-activated cell sorting, and screened by [ 3 H]AVP binding. Ltk-cells were transfected with the cDNA coding for the human OT receptor. CHO-DHFR-cells (DXB11; CRL-9096; ATCC) were transfected with an expression vector derived from plasmid 7055 containing the cDNA encoding the human V 2, V1a, or V1bR. Stably transformed cell lines were isolated as described earlier (24, 46, 34) .
Pituitary tissues, without microscopic abnormalities or tumors, and myometrial biopsies obtained from pregnant women with normal uncomplicated pregnancies who were delivered by elective caesarean section before the onset of labor (38 -40 wk of pregnancy) were immediately frozen after excision for autoradiography studies. Human tissue samples were collected in conformity with French national ethical rules. This project was approved by human subject review committees and was carried out in collaboration with the Pathological Anatomy Department of the University Hospitals of Strasbourg and Dijon. The protocols for the animal studies were approved by the animal care and use committee of sanofi-aventis research and development.
Cell culture. In-R1-G9 cells were cultured in RPMI-1640 medium with 10% FBS, 0.03% amphotericin, 0.2% penicillin/streptomycin, and 2 mM L-glutamine. They were grown at 37°C in a humidified atmosphere of CO2. All experiments were performed using cells from passages 22 to 36. Transfected AtT20 cells were cultured in DMEM-F-12 supplemented with 7.5% Fetalclone, 7.5% Nu-serum, 0.5 mM glutamine, and 0.2 mg/ml G418 at 37°C in a 5% CO2 atmosphere. Transfected Ltk-and CHO cells were grown in 10 mM HEPES, pH 7.4, and minimal essential medium supplemented with 5% FCS serum, 8 g/l sodium bicarbonate, and 0.3 mg/ml G418 at 37°C in a humidified atmosphere containing 5% CO2. Wild-type cells were routinely grown in a similar culture medium without the selective agent G418. The culture medium was removed every other day, and cells were subcultured by treatment with 0.05% trypsin and 0.02% EDTA.
Membrane preparation. Membranes from In-R1-G9 and CHO cells expressing the human or the rat V1bR, AtT20 cells expressing the murine or the human V1bR, LtK-cells expressing the human oxytocin receptor, and CHO cells expressing human V1a and V2 receptors were prepared as described by Serradeil-Le Gal et al. (34) . Briefly, cells were harvested, washed two times in PBS without Ca 2ϩ and Mg 2ϩ , polytron-homogenized in lysis buffer (15 mM Tris ⅐ HCl, pH 7.5, 2 mM MgCl2, and 0.3 mM EDTA), and centrifuged at 100 g for 5 min at 4°C. Pellets were washed in 50 mM Tris ⅐ HCl, pH 7.4, and 5 mM MgCl2 (buffer A) and centrifuged at 44,000 g for 20 min at 4°C.
Membranes were suspended in a small volume of buffer A, and protein contents were determined by the method of Bradford using BSA as a standard (5 (34) .
Autoradiography. Serial sections (16 m thick) from frozen whole rat pituitaries or human pituitary samples were mounted on gelatin chrome-alum slides, rinsed to eliminate endogenous AVP, and incubated with 5 nM [
3 H]SSR-149415 with (nonspecific binding) or without (total binding) 1 M unlabeled SSR-149415. After 60 min incubation at room temperature, the sections were washed three times for 10 min each in ice-cold binding buffer, dipped briefly in distilled water, and dried under a stream of cold air. Rinsed labeled sections were placed on a phosphor-imaging plate (Fuji) for 1 to 2 wk and further analyzed with a Bio-Image Analyzer (BAS 2000; Fuji) as previously described (36) . Similar experiments were performed on human pregnant uterus sections using
125 I]OVTA (0.05 nM) as ligands and 10 M unlabeled OT for determination of nonspecific binding as previously described (37) .
IP assays. IP production was determined as previously described (10) . Briefly, AtT20 cells stably transfected with the mouse or human V 1bR were plated at 100,000 cells/well. Cells were grown for 24 h in their respective culture medium (see above) and further incubated for another 24 h in a serum-and inositol-free medium supplemented with 1 Ci/ml-1 myo- [2- 3 H]inositol. Cells were then washed two times with Hanks' buffer saline medium, incubated for 15 min in this medium supplemented with 20 mM LiCl, and further stimulated for 15 min with increasing concentrations of analogs to be tested. The reaction was stopped by adding perchloric acid (5% vol/vol). Total accumulated IP was extracted, purified on Dowex AGI-X8 anion exchange chromatography columns as previously described (9), and counted. Data were analyzed using the RS1 software (BBN Domain, Cambridge, MA). Values are expressed as means Ϯ SD of at least three independent experiments.
Intracellular Ca
2ϩ concentration measurements. Subconfluent CHO and AtT20 cells, cultured in 175-cm 2 flasks as described above, were collected by trypsinization (0.05% trypsin, 0.02% EDTA) and centrifuged (230 g, 5 min). At 80% confluency, cells were transfected with 4 g aequorin plasmid expression vector using the Lipofectamine 2000 reagent (18); 24 h after transfection, medium was removed, and cells were detached using PBS/5 mM EDTA and incubated for 3 h at a concentration of 2ϫ10 6 cells/ml in DMEM-F-12 medium without phenol red (Invitrogen) supplemented with 0.1% FCS and 5 M coelenterazine (Molecular Probes). Cells were diluted 10-fold in the same medium and incubated for an additional 3-h period. Loaded cell suspension (100 l) was distributed in 96-well microplates, and then cells were incubated with increasing concentrations of agonists alone or with the nonpeptide antagonists SSR-149415 and SSR-149424 15 min before adding 10 nM AVP. Light emission was recorded for 60 s using a Luminoskan microplate luminometer (Labsystems), and the data were expressed in relative light units. After the 60-s measurement period, cells were lysed using 100 l PBS-2.5% Triton X-100 -50 mM CaCl 2, and luminescence induced corresponding to the nonmobilized cell Ca 2ϩ was recorded. Each assay was carried out in triplicate. Luminescence data (peak integration) were calculated and expressed as percent of the maximal luminescence recorded (i.e., sum of sample and lysis luminescence recordings). Data were analyzed using the RS1 software (BBN Domain). Values are expressed as means Ϯ SD of at least three independent experiments.
Time-lapse confocal videomicroscopy. AtT20 cells stably expressing the EGFP-tagged human or mouse V 1bR were plated in Lab-Tek chambered coverglasses (Nunc, Dominique Dutcher, Brumath, France). Later (2 days), culture medium was replaced by DMEM-F-12 devoid of phenol red and supplemented with 0.2% dialyzed BSA and 25 mM HEPES, pH 7.4. The cells were placed on the stage of a Leica TCS SP2 AOBS confocal microscope laid in a thermostated chamber at 37°C. Images were acquired every 30 s for up to 45 min in recycling experiments. Between the second and the third image, drugs were added to the cells on the stage of the microscope, the time was set to zero, and image collection continued. When required, a second treatment was added at the times indicated in the legend to Fig. 6 . AVP (0.1 M) and SSR-149415 (1 M) were used. Each experiment was carried out at least two times, yielding similar results.
RESULTS

Tritiation of SSR-149415.
For the incorporation of the tritium label, the 2,4-dimethoxyphenol positions of SSR-149415 were chosen (Fig. 1) . Therefore, the dihydroxyl precursor of SSR-149415 was methylated using high-specific-activity (Fig. 1) . The specific activity was calculated to be 81 Ci/mmol, and, after purification by high-pressure liquid chromatography, a radiochemical purity of 99.0% was obtained.
Characterization of [ 3 H]SSR-149415 Binding to Animal and Human AVP V1 b R Kinetics experiments. [
3 H]SSR-149415 binding was characterized in the various cell lines expressing either recombinant (CHO, AtT20) or constitutive (In-R1-G9) V 1b R from rodent (mouse, rat, and hamster) and human origin. Using the different cell membranes, we showed that [ 3 H]SSR-149415 specific binding increased linearly as a function of the membrane protein concentration and then reached (or tended to reach) saturation as shown in Fig. 2 on membranes of CHO or AtT20 cells expressing either the human or the mouse V 1b R, respectively. For each membrane preparation, a protein concentration in the linear portion of the curve was chosen for subsequent binding studies.
As shown in Fig. 2 to 18 nM (Fig. 3A) . Scatchard plot analysis obtained from saturation isotherms gave in each case linear plots consistent with the presence of a single class of high-affinity binding sites as shown in Fig. 3B using both (Table 1) .
Competition binding studies. The relative affinities of several reference peptide and nonpeptide AVP/OT ligands were studied to characterize the binding of Another set of competition studies was performed using peptide ligands (Fig. 4, B and D) . AVP and the selective V 1b agonist ligand recently described, d [Cha 4 ]AVP, showed nano- Values are means Ϯ SD. Data for equilibrium binding ͓apparent equilibrium dissociation constant (Kd) and maximum binding density (Bmax)͔ were measured as described in METHODS and analyzed using an iterative nonlinear regression program (34) .V1bR, vasopressin type 1b (V1b) receptor; AVP, arginine vasopressin. (Fig. 4, B and D (36) . All the AVP/OT ligand affinities measured in the different preparations from mouse, rat, hamster, and human origin are reported in Table 2 and confirm in every case a rank order of affinity compatible with a V 1b R profile. These data also highlight species differences existing for both peptide (dPal, dDAVP, dPen) and nonpeptide (SSR-126768A, SR-49059) compounds that are very common in the AVP/OT field.
Specificity of [ 3 H]SSR-149415
The selectivity of SSR-149415 for the V 1b R was previously demonstrated in a wide number of assays for receptors, enzymes, and ion channels (n ϭ 100) in which lack of interaction was observed up to 10 M (39). In the present study, using various native tissues such as rat liver or kidney constitutively expressing the V 1a and the V 2 R, respectively, and CHO cells transfected or not with the human V 1a , V 2 (Fig. 5) . Intense specific labeling totally displaced by 10 M SSR-149415 (or 10 M AVP; data not shown) was observed in human sections obtained from three different pituitary samples (Fig. 5A ). An irregular patchy signal of high density was observed in corticotrophs. In the rat pituitary, a fainter specific signal was observed in the anterior pituitary, whereas a high level of nonspecific binding was obtained in the central neural lobe, and no specific labeling was detected in the intermediate lobe area as previously described with [ 3 H]AVP (45). Using [ 3 H]AVP as a reference ligand, we obtained a similar labeling signal confined to corticotrophs on these preparations (data not shown).
In autoradiographic studies performed on reference human tissues expressing V 1a (liver), V 2 (kidney) (data not shown) or OTR (pregnant uterus), no specific labeling was observed with [ 3 H]SSR-149415, in particular in the pregnant uterus, which expresses significant amounts of high-affinity OTR sites distinctly labeled by the native tritiated hormone [ 3 H]OT (Fig. 6 ). Of note, these data do not support the SSR-149415 interaction (effect similar to that of OT itself) at human recombinant OTR recently reported by Griffante et al. (17) . Additional experiments with [ 3 H]SSR-149415 to address V 1b R localization in rat brain sections failed to show clear specific labeling in CNS structures (data not shown). The limited specific activity of the tritium label associated with low levels of V 1b R is probably the main difficulty that will have to be overcome to map extrapituitary V 1b R, especially in the brain. An absence of specific binding was also observed in rat brain membranes using Table 3 ). As shown in Fig. 7A , SSR-149415 dose-dependently and totally antagonized 10 nM AVP-induced IP production with IC 50 values of 12.3 Ϯ 8.4 and 11.00 Ϯ 9.8 nM for the mouse and human V 1b R, respectively. Of note, this effect was stereospe- Under similar operating conditions, the AVP-related hormone OT exhibited an agonist profile, although it was much less potent than AVP (at least Ͼ54-fold; Table 4 ). SSR-149415 competed as a potent antagonist in inhibiting AVP-evoked intracellular Ca 2ϩ elevation in a dose-dependent manner, yielding nanomolar IC 50 values for the mouse and human recombinant V 1b R (Fig. 7B ). This effect was stereospecific, since SSR-149415's diasteroisomer, SSR-149424, was much less efficient (about 3 orders of magnitude) and gave IC 50 in the micromolar range (Table 4) .
Effect of SSR-149415 on AVP-induced V 1b R internalization in AtT20 cells.
The functional effect of SSR-149415 on AVP-induced internalization was investigated by time-lapse confocal videomicroscopy using AtT20 cells stably expressing either mouse or human EGFP-tagged V 1b R. The EGFP tag did not alter the affinity of the hV 1b R or the mV 1b R, since the K d measured in membrane preparations using [ 3 H]AVP as a ligand was in the range of that of the wild type, 0.23 vs. 0.95 and 1.16 vs. 0.67 nM, respectively. As shown in Fig. 8A , SSR-149415 (10 Ϫ6 M) by itself had no effect on receptor traffic, but totally prevented the internalization induced by 10 Ϫ7 M AVP (Fig. 8B) . Moreover, SSR-149415 (10 Ϫ6 M) treatment allowed observation of the recycling to the cell membrane of V 1b R previously internalized by AVP pretreatment (Fig. 8C) . Similar results were obtained whatever the species considered.
DISCUSSION
Despite a large panoply of vasopressin analogs designed to target each AVP receptor subtype and thus to determine specificity and function, until recently, the characterization of the V 1b R was severely hampered by the lack of specific highaffinity ligands directed toward this receptor. The present work provides a detailed biochemical characterization of [ 3 H]SSR-149415, the first antagonist radioligand available so far for labeling rodent and human V 1b R. Our data indicate that, in binding studies, [ 3 H]SSR-149415 displays high affinity and specificity for the mouse, hamster, rat and human V 1b R and constitutes a suitable probe for mapping these receptors. Additionally, using SSR-149415/[
3 H]SSR-149415, the mouse V 1b R stably expressed in murine AtT20 pituitary cells was, for the first time, extensively characterized in comparison with the human one in terms of binding properties and signaling as measured by IP production, Ca 2ϩ mobilization, and receptor internalization.
Radioligand binding experiments using [ 3 H]SSR-149415 and a variety of reference AVP/OT receptor agonists and antagonists showed that [ 3 H]SSR-149415 presented similar properties at V 1b R sites from mouse, hamster, rat, and human origin. In each case, [ 3 H]SSR-149415 binding was time and protein concentration dependent, reversible stereospecific, and saturable. A single high-affinity population of binding sites in the nanomolar range was identified in agreement with K i values previously obtained with SSR-149415 for the rat, bovine, and human pituitary V 1b isoform (39) . In contrast to previous results reported in the mouse (28) , the affinity of SSR-149415 was also found excellent (i.e., nanomolar) for the murine V 1b R with a selectivity ratio Ͼ50-fold between the mouse V 1b and the other AVP/OT receptors. In the different preparations, Tables 1 and 2 ). In fact this natural cell line expresses a very low level of native V 1b R (45 fmol/mg protein) which could induce a variability in our results in comparison with the higher number (Ͼ100-fold) of recombinant V 1b R expressed in CHO or AtT20 cells. A certain variability in affinity as a function of cell culture passages could also explain this small difference. Functional experiments performed on the mouse V 1b R in murine AtT20 pituitary cells confirmed the strong interaction with the murine V 1b R, since SSR-149415 antagonized both AVP-induced IP production and [Ca 2ϩ ] increase with nanomolar efficiency. Interestingly, binding data also showed that SSR-149415 had an affinity similar to that of the natural hormone AVP at the V 1b R and underlined the absence of species differences for the molecule. This constant high affinity is a remarkable property in a field where commonly peptide or nonpeptide ligands targeting AVP/OT receptors can lose totally, or partially, their affinity and selectivity or have their functional pharmacological properties modified depending on the species (29, 33, 42, 18) . As an illustration, the variable binding affinity of some peptide (dPal, dDAVP) and nonpeptide (SSR-126768A, SR-49059) compounds is supportive of species-dependent V 1b R affinity in our study (Table 2) .
In terms of biological function, the pituitary V 1b R is mainly involved in the stimulating effect of AVP on ACTH secretion as a direct ACTH secretagogue or in combination with CRF in several species, including humans, and thus controls the stress response (14, 30, 13, 11) . It was shown that in vivo SSR-149415 directly interacted at rat pituitary V 1b R in inhibiting elevated ACTH secretion by various stimulants such as hormones (AVP, AVP ϩ CRF) and physical stress (restraint stress, dehydration; see Ref. 39) . Interestingly, this molecule attenuates anxiety and stress-related behaviors and exerts marked antidepressant-like activity in rodents (16 However, despite literature data reporting the presence of rat brain V 1b R mRNA or protein, we failed to evidence specific V 1b R binding sites on rat brain membranes or sections using in situ autoradiography. Recently, we confirmed the antidepressant-like effects of SSR-149415 in the forcedswimming test following specific intracerebroventricular injections in the lateral septum, giving further convincing evidence of the presence of V 1b R in the rat central nervous system (CNS) and showing a central component in the mechanism of action of our compound (40) . In fact, the low expression levels of V 1b R in only some specific brain areas or nuclei, associated with the well-known low specific activity of tritium, are major drawbacks for labeling these receptors in the brain, and one should expect better results with a V 1b radioiodinated ligand. Indeed, discrete expression of V 1b R is a common feature either in extrapituitary tissues (pancreas, kidney, adrenals. . . .) or in some cell lines constitutively expressing these receptors (small-cell lung cancer, bronchial epithelial, or pancreatic cells . . .). As an illustration, the natural glucagon-secreting pancreatic cell line In-R1-G9 studied in the present work exhibited low maximal binding capacity (45 fmol/mg protein, 7,000 sites/cell; Table 1 (35, 36) . In fact all of these molecules are hydrophobic radioligands that can bind AVP receptors either from right side-out or right side-in vesicles generated during membrane preparation, whereas [ 3 H]AVP, as an hydrophylic peptide, can only target externally accessible V 1a , V 1b , or V 2 receptor sites. These nonpeptide molecules belong to a class of membrane-permeant antagonists called "pharmacological chaperones" that are able to interact with both cell surface and intracellular receptors and even, as demonstrated for SR-121463, to rescue natural misfolded endoplasmic reticulum V 2 R mutants responsible for nephrogenic diabetes insipidus (25) . To date, V 1b R overexpression has been reported in some corticotrophin-secreting tumors (9), but no natural mutation of the V 1b R has been associated with diseases. However, an endoplasmic reticulum-retained V 1b R mutant was generated by site-directed mutagenesis, and, in such a situation, SSR-149415 behaves as a pharmacological chaperone and rescues maturation by promoting correct cell-surface expression and the signaling function of the artificial mutant (31) . Natural mutations may also exist for the V 1b R but may be more difficult to detect than V 2 R ones associated with obvious clinical signs such as dramatic diuresis.
The selectivity of SSR-149415 was confirmed in binding studies using (Fig. 6 ). Of note, these data did not support the reported interaction of SSR-149415 (almost similar to that of OT itself) at human recombinant OTR (17) . The discrepancy could be due to different experimental conditions (ligand, source of receptors . . .). However, the properties of the OTR could also be modified in recombinant cells and vary as a function of the OTR number or environment. That is why we choose to use in our study pregnant tissue samples expressing the native OTR to address the intrinsic affinity of SSR-149415 and its tritiated form under physiological and native conditions. It is well known that the OTR in pregnant tissue exhibited exacerbated affinity for the natural hormone and could exist as homo/heterodimers in particular with the V 1a R also expressed in the uterus (43) . Additionally, membrane lipidic/ cholesterol environment also strikingly modifies OTR affin- ity (21) and could explain these different results obtained under in vitro binding and ex vivo autoradiographic conditions.
Finally, functional characterization of SSR-149415 at the V 1b R was performed on earlier cellular events, upstream of corticotrophin release, such as AVP activation of IP production, intracellular [Ca 2ϩ ] i mobilization, and receptor internalization. SSR-149415 presents a full, stereospecific antagonist profile at mouse and human V 1b R on AVP-induced IP accumulation and [Ca 2ϩ ] i elevation with nanomolar efficiency, and the much lower potency of SSR-149415's diasteroisomer was consistent with data from binding studies in these cells. SSR-149415 inhibition was dose dependent. No agonistic effects were observed when tested alone. Pure antagonist properties for this molecule were further confirmed on the basis of our confocal microscopy data performed on AtT20 cells stably expressing the EGFP-tagged human or mouse V 1b R. SSR-149415 (1 M) had no effect by itself on V 1b R traffic but blocked V 1b R internalization following AVP stimulation (Fig.  8, A and B) . Interestingly, SSR-149415 (1 M) was able to restore to the membrane V 1b R previously internalized by AVP by interrupting the endocytosis process (Fig. 8C) . The V 1b R is a class A-type receptor undergoing dynamic endocytosis and rapid recycling (30 min) upon agonist stimulation (Ventura, unpublished observations). Other receptors such as V 1a R, ␤-adrenergic, and opiate also belong to this class, in contrast to V 2 R, a class B-type receptor, which is also internalized, but is recycled more slowly (2 h) and is mainly degraded in the lysosomal compartment (27, 4) . As expected, the V 1b antagonist totally blocked the endocytosis process initiated by AVP in AtT20 cells and favored the observation of receptor recycling to the membrane as shown at time 40 min in our experiments (Fig. 8C) .
Of the four AVP/OT receptor subtypes cloned so far, the V 1b R had been poorly characterized because of its limited and scarce expression, even in the pituitary, and the lack of V 1b R agonist or antagonist ligands. Using [ increase, and V 1b R internalization). Thus the orally active V 1b R antagonist SSR-149415 and its tritiated form constitute unique tools for further exploring the biological role and functions of V 1b R.
